Brought to you by 
Auris Medical advances tinnitus drug therapy development with funds from CHF47.1mm Series C round
31 May 2013
Executive Summary
Auris Medical AG (developing drug therapies for inner ear disorders) raised CHF47.1mm ($50.3mm) through its Series C round. Sofinnova Ventures and Sofinnova Partners participated, and both gain representation on Auris’s board.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Auris Medical advances tinnitus drug therapy development with funds from CHF47.1mm Series C round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice